Currently, no commercially available drugs have the ability to reverse cachexia or counteract muscle wasting and the loss of lean mass. Here, we report the methodology used to develop Physiactisome-a conditioned medium released by heat shock protein 60 (Hsp60)-overexpressing C2C12 cell lines enriched with small and large extracellular vesicles. We also present evidence supporting its use in the treatment of cachexia. Briefly, we obtain a nanovesicle-based secretion by genetically modifying C2C12 cell lines with an Hsp60-overexpressing plasmid. The secretion is used to treat naïve C2C12 cell lines. Physiactisome activates the expression of PGC-1α isoform 1, which is directly involved in mitochondrial biogenesis and muscle atrophy suppression, in naïve C2C12 cell lines. Proteomic analyses show Hsp60 localisation inside isolated nanovesicles and the localisation of several apocrine and merocrine molecules, with potential benefits for severe forms of muscle atrophy. Considering that Physiactisome can be easily obtained following tissue biopsy and can be applied to autologous muscle stem cells, we propose a potential nanovesicle-based anti-cachexia drug that could mimic the beneficial effects of exercise. Thus, Physiactisome may improve patient survival and quality of life. Furthermore, the method used to add Hsp60 into nanovesicles can be used to deliver other drugs or active proteins to vesicles.

Physiactisome: a new nanovesicle drug containing heat shock protein 60 for treating muscle wasting and cachexia / Di Felice, Valentina; Barone, Rosario; Trovato, Eleonora; D'Amico, Daniela; Macaluso, Filippo; Campanella, Claudia; Marino Gammazza, Antonella; Muccilli, Vera; Cunsolo, Vincenzo; Cancemi, Patrizia; Multhoff, Gabriele; Coletti, Dario; Adamo, Sergio; Farina, Felicia; Cappello, Francesco. - In: CELLS. - ISSN 2073-4409. - 9:11(2022), pp. 1-17. [10.3390/cells11091406]

Physiactisome: a new nanovesicle drug containing heat shock protein 60 for treating muscle wasting and cachexia

Dario Coletti;Sergio Adamo;
2022

Abstract

Currently, no commercially available drugs have the ability to reverse cachexia or counteract muscle wasting and the loss of lean mass. Here, we report the methodology used to develop Physiactisome-a conditioned medium released by heat shock protein 60 (Hsp60)-overexpressing C2C12 cell lines enriched with small and large extracellular vesicles. We also present evidence supporting its use in the treatment of cachexia. Briefly, we obtain a nanovesicle-based secretion by genetically modifying C2C12 cell lines with an Hsp60-overexpressing plasmid. The secretion is used to treat naïve C2C12 cell lines. Physiactisome activates the expression of PGC-1α isoform 1, which is directly involved in mitochondrial biogenesis and muscle atrophy suppression, in naïve C2C12 cell lines. Proteomic analyses show Hsp60 localisation inside isolated nanovesicles and the localisation of several apocrine and merocrine molecules, with potential benefits for severe forms of muscle atrophy. Considering that Physiactisome can be easily obtained following tissue biopsy and can be applied to autologous muscle stem cells, we propose a potential nanovesicle-based anti-cachexia drug that could mimic the beneficial effects of exercise. Thus, Physiactisome may improve patient survival and quality of life. Furthermore, the method used to add Hsp60 into nanovesicles can be used to deliver other drugs or active proteins to vesicles.
2022
cachexia; exercise; exosome; muscle atrophy; muscle wasting; sarcopenia
01 Pubblicazione su rivista::01a Articolo in rivista
Physiactisome: a new nanovesicle drug containing heat shock protein 60 for treating muscle wasting and cachexia / Di Felice, Valentina; Barone, Rosario; Trovato, Eleonora; D'Amico, Daniela; Macaluso, Filippo; Campanella, Claudia; Marino Gammazza, Antonella; Muccilli, Vera; Cunsolo, Vincenzo; Cancemi, Patrizia; Multhoff, Gabriele; Coletti, Dario; Adamo, Sergio; Farina, Felicia; Cappello, Francesco. - In: CELLS. - ISSN 2073-4409. - 9:11(2022), pp. 1-17. [10.3390/cells11091406]
File allegati a questo prodotto
File Dimensione Formato  
Di Felice_Physiactisome_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 4.28 MB
Formato Adobe PDF
4.28 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1640147
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact